Rhumbline Advisers Halozyme Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 404,675 shares of HALO stock, worth $18.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

404,675

Previous 424,496 4.67%

Holding current value

$18.5 Million

Previous $22.2 Million 4.16%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$51.3 - $64.42 $1.02 Million - $1.28 Million	-19,821 Reduced 4.67%	404,675 $23.2 Million
Q2 2024 Aug 01, 2024	SELL	$37.81 - $52.4 $277,222 - $384,196	-7,332 Reduced 1.7%	424,496 $22.2 Million
Q1 2024 May 09, 2024	BUY	$33.68 - $41.95 $89,723 - $111,754	2,664 Added 0.62%	431,828 $17.6 Million
Q4 2023 Feb 08, 2024	SELL	$33.32 - $42.1 $386,178 - $487,939	-11,590 Reduced 2.63%	429,164 $15.9 Million
Q3 2023 Nov 09, 2023	SELL	$36.46 - $44.03 $263,459 - $318,160	-7,226 Reduced 1.61%	440,754 $16.8 Million
Q2 2023 Aug 08, 2023	SELL	$30.28 - $38.74 $476,243 - $609,302	-15,728 Reduced 3.39%	447,980 $16.2 Million
Q1 2023 May 11, 2023	BUY	$32.86 - $55.7 $214,312 - $363,275	6,522 Added 1.43%	463,708 $17.7 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $284,185 - $421,667	7,094 Added 1.58%	457,186 $26 Million
Q3 2022 Nov 10, 2022	BUY	$38.53 - $51.78 $525,934 - $706,797	13,650 Added 3.13%	450,092 $17.8 Million
Q2 2022 Aug 11, 2022	BUY	$37.35 - $48.3 $771,053 - $997,105	20,644 Added 4.96%	436,442 $19.2 Million
Q1 2022 May 12, 2022	BUY	$31.97 - $41.06 $12,276 - $15,767	384 Added 0.09%	415,798 $16.6 Million
Q4 2021 Feb 10, 2022	SELL	$31.82 - $40.75 $70,131 - $89,813	-2,204 Reduced 0.53%	415,414 $16.7 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $594,399 - $717,235	15,451 Added 3.84%	417,618 $17 Million
Q2 2021 Aug 05, 2021	BUY	$38.84 - $51.31 $672,631 - $888,586	17,318 Added 4.5%	402,167 $18.3 Million
Q1 2021 May 06, 2021	SELL	$39.51 - $51.45 $820,109 - $1.07 Million	-20,757 Reduced 5.12%	384,849 $16 Million
Q4 2020 Feb 10, 2021	BUY	$25.81 - $43.62 $5.37 Million - $9.08 Million	208,204 Added 105.47%	405,606 $17.3 Million
Q3 2020 Nov 12, 2020	SELL	$25.74 - $29.63 $1.57 Million - $1.81 Million	-61,062 Reduced 23.62%	197,402 $5.19 Million
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $559,455 - $923,014	34,428 Added 15.37%	258,464 $6.93 Million
Q1 2020 May 06, 2020	SELL	$13.9 - $21.83 $56,169 - $88,215	-4,041 Reduced 1.77%	224,036 $4.03 Million
Q4 2019 Feb 05, 2020	BUY	$14.93 - $19.53 $162,274 - $212,271	10,869 Added 5.0%	228,077 $4.04 Million
Q3 2019 Oct 23, 2019	BUY	$15.2 - $17.69 $34,990 - $40,722	2,302 Added 1.07%	217,208 $3.37 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $550,706 - $644,419	37,336 Added 21.03%	214,906 $3.69 Million
Q1 2019 May 01, 2019	SELL	$13.94 - $17.58 $21,314 - $26,879	-1,529 Reduced 0.85%	177,570 $2.86 Million
Q4 2018 Jan 31, 2019	BUY	$13.33 - $18.66 $745,626 - $1.04 Million	55,936 Added 45.42%	179,099 $2.62 Million
Q3 2018 Nov 07, 2018	SELL	$16.68 - $18.41 $160,478 - $177,122	-9,621 Reduced 7.25%	123,163 $2.24 Million
Q2 2018 Aug 06, 2018	BUY	$16.87 - $20.3 $146,819 - $176,670	8,703 Added 7.01%	132,784 $2.24 Million
Q1 2018 May 02, 2018	SELL	$17.06 - $21.2 $46,573 - $57,876	-2,730 Reduced 2.15%	124,081 $2.43 Million
Q4 2017 Feb 09, 2018	SELL	$16.75 - $20.8 $276,894 - $343,844	-16,531 Reduced 11.53%	126,811 $2.57 Million
Q3 2017 Nov 06, 2017	BUY	$11.76 - $17.4 $1.69 Million - $2.49 Million	143,342	143,342 $2.49 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.37B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Halozyme Therapeutics, Inc. Transaction History